Mode
Text Size
Log in / Sign up

Pulmonary Arterial Hypertension

Part of Hypertension

Subtypes of Pulmonary Arterial Hypertension

Connective tissue disease-associated pulmonary arterial hypertension 1 Sjögren’s syndrome-associated pulmonary arterial hypertension 1 Systemic lupus erythematosus-associated pulmonary arterial hypertension 1 Systemic sclerosis-associated pulmonary arterial hypertension 1

7 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Pulmonary Arterial Hypertension

102 trials tracked for Pulmonary Arterial Hypertension: 53 in phase 3 or 4 and 22 with published results. The most-cited published study has 644 citations.

102Trials tracked
53Phase 3 & 4
0Recruiting
22With published results
Phase distribution
Phase 4 19 Phase 3 34 Phase 2 33 Phase 1 5 Other / NA 11
  1. Phase 3 A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR) Completed · 644 cited
  2. Phase 4 A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis Completed · 167 cited
  3. Phase 3 The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension Completed · 165 cited
  4. Phase 4 Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy Completed · 160 cited
  5. Phase 3 Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy Completed · 152 cited
  6. Phase 3 Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome Completed · 126 cited
Show 44 more trials
  1. Phase 3 A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH) Completed · 104 cited
  2. Phase 3 Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument Completed · 65 cited
  3. Phase 4 Management of Acute Pulmonary Hypertensive Crisis in Children With Known Pulmonary Arterial Hypertension Completed · 60 cited
  4. Phase 4 REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension Completed · 53 cited
  5. Phase 3 Bosentan in Children With Pulmonary Arterial Hypertension Extension Study Completed · 45 cited
  6. Phase 4 Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension. Completed · 34 cited
  7. Phase 3 Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension Completed · 33 cited
  8. Phase 3 ACT-293987 in Pulmonary Arterial Hypertension Completed · 33 cited
  9. Phase 3 Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension Completed · 16 cited
  10. Phase 3 A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007) Completed · 12 cited
  11. Phase 4 EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension Completed · 8 cited
  12. Phase 3 Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension Completed · 7 cited
  13. Phase 3 An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension Completed · 5 cited
  14. Phase 4 Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication Completed · 4 cited
  15. Phase 3 A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020) Completed · 2 cited
  16. Phase 3 A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH) Completed
  17. Phase 4 BREATHE 5-OL: Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology Completed
  18. Phase 4 Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension Completed
  19. Phase 4 TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH) Completed
  20. Phase 4 Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID) Completed
  21. Phase 4 Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension Completed
  22. Phase 4 Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects Completed
  23. Phase 4 Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401 Completed
  24. Phase 4 Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH) Completed
  25. Phase 4 Combination Therapy in Pulmonary Arterial Hypertension Completed
  26. Phase 4 Epoprostenol for Injection in Pulmonary Arterial Hypertension Completed
  27. Phase 4 Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension Completed
  28. Phase 4 Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1) Completed
  29. Phase 3 A Pharmacokinetic Substudy of the TDE-PH-304 Protocol Completed
  30. Phase 3 Epoprostenol for Injection in Patients With Pulmonary Arterial Hypertension Completed
  31. Phase 3 Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension Completed
  32. Phase 3 FUTURE 3 Study Extension Completed
  33. Phase 3 Beraprost-314d Added-on to Tyvaso® (BEAT) Completed
  34. Phase 3 An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension Completed
  35. Phase 3 Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants Completed
  36. Phase 3 A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension Completed
  37. Phase 3 Epoprostenol for Injection (EFI/ACT-385781A) - Pulmonary Arterial Hypertension Completed
  38. Phase 3 A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children Completed
  39. Phase 3 A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202) Completed
  40. Phase 3 Selexipag (ACT-293987) in Pulmonary Arterial Hypertension Completed
  41. Phase 3 Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension Completed
  42. Phase 3 Ranolazine and Pulmonary Hypertension Completed
  43. Phase 3 Iloprost Power 15 in Pulmonary Arterial Hypertension Completed
  44. Phase 3 Imatinib (QTI571) in Pulmonary Arterial Hypertension Completed

Showing the 50 most-cited and recently-updated of 102 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Hypertension

Related studies from across the Hypertension family.

Evaluating the Impact of Digital Health Interventions on Chronic Disease Self-Care Outcomes
Physical Medicine & Rehab Meta-analysis
Evaluating the Impact of Digital Health Interventions on Chronic Disease Self-Care Outcomes Digital health tools show mixed results for managing chronic diseases
Digital tools show promise for heart failure monitoring but lack consistent evidence for improving medication adherence or general diabetes …
New data shows that while digital tools like apps can help heart failure patients monitor their health, they may not improve medication habi…
Ambulatory hypertension in pediatric chronic kidney disease patients increases risk of left ventricular hypertrophy
Pediatrics Meta-analysis
Ambulatory hypertension in pediatric chronic kidney disease patients increases risk of left ventricular hypertrophy High Blood Pressure Linked to Heart Changes in Children
This meta-analysis of 51 studies involving 6509 children with chronic kidney disease found that ambulatory hypertension is associated with i…
New data shows a strong link between high blood pressure and heart muscle thickening in children with chronic kidney disease.
Pharmacist-led telepharmacy may improve medication adherence and reduce blood pressure in patients with NCDs
Cardiology Sys. Review
Pharmacist-led telepharmacy may improve medication adherence and reduce blood pressure in patients with NCDs Pharmacist Led Telepharmacy May Improve Medication Adherence For Chronic Illness
This systematic review analyzed 21 trials involving 5440 participants to evaluate pharmacist-led telepharmacy for managing non-communicable …
Remote pharmacist services through phone or video may help patients with high blood pressure and diabetes stick to their daily medication pl…
Individualized six-phase antithrombotic strategy leads to left ventricular thrombus resolution and neurological recovery
Drug Pipeline Guideline
Individualized six-phase antithrombotic strategy leads to left ventricular thrombus resolution and neurological recovery New strategy helps manage heart blood clots after heart attack
This case report describes an individualized six-phase antithrombotic strategy for a 27-year-old male with myocardial infarction, stroke, hy…
A tailored six-phase treatment plan helped a young man recover fully from a stroke and heart attack while successfully clearing dangerous bl…
Multi-target therapies may address combined hypertension and dyslipidemia pathophysiology
Cardiology Sys. Review
Multi-target therapies may address combined hypertension and dyslipidemia pathophysiology Multi-Target Therapies May Address Combined Hypertension and High Cholesterol
This systematic review synthesizes evidence on synergistic mechanisms of hypertension and dyslipidemia, highlighting the RAAS/PPAR axis, AMP…
Combining treatments like statins and RAAS inhibitors may offer a more precise way to manage both high blood pressure and cholesterol levels…
Bedtime antihypertensive dosing shows no cardiovascular benefit over morning dosing
Cardiology Meta-analysis
Bedtime antihypertensive dosing shows no cardiovascular benefit over morning dosing Bedtime vs. Morning Blood Pressure Meds: No Clear Winner
A meta-analysis of randomized trials compared bedtime versus morning administration of antihypertensives. No evidence of a difference in maj…
Taking blood pressure medication at bedtime did not reduce heart attacks, strokes, or deaths more than morning dosing in a large analysis of…
Preoperative comorbidities linked to reduced weight loss after metabolic and bariatric surgery in adults
Nutrition & Obesity Medicine Meta-analysis
Preoperative comorbidities linked to reduced weight loss after metabolic and bariatric surgery in adults Pre-existing health conditions may slightly reduce weight loss after surgery
A meta-analysis of twenty-three studies reveals that mental illness, diabetes, and sleep apnea are associated with slightly lower weight los…
Adults with mental illness or diabetes before surgery saw slightly less weight loss. Other conditions like high blood pressure did not affec…
Renal denervation value framework prioritizes efficacy and safety for Chinese hospital procurement
Primary Care & Family Medicine Sys. Review
Renal denervation value framework prioritizes efficacy and safety for Chinese hospital procurement Experts build framework to assess renal denervation therapy value in China
This narrative review constructs a comprehensive value assessment framework for renal denervation (RDN) therapy in Chinese hospitals. The fr…
A new framework helps Chinese hospitals evaluate renal denervation therapy by weighing factors like safety, efficacy, and patient value.
Eating later in the biological day is associated with impaired glucose regulation and reduced insulin sensitivity
Nutrition & Obesity Medicine Sys. Review
Eating later in the biological day is associated with impaired glucose regulation and reduced insulin sensitivity Eating later in the day is linked to worse blood sugar and heart health markers
This narrative review examines chrononutrition in obesity, type 2 diabetes, hypertension, and cardiovascular disease. Findings indicate that…
A review suggests eating later in the biological day is associated with impaired glucose regulation and reduced insulin sensitivity in peopl…
Bosentan lowers treatment failure risk in neonates with persistent pulmonary hypertension of the newborn by 73%
Pediatrics Meta-analysis
Bosentan lowers treatment failure risk in neonates with persistent pulmonary hypertension of the newborn by 73% Bosentan therapy lowers treatment failure for newborns with persistent lung pressure issues
This systematic review and meta-analysis evaluated bosentan for persistent pulmonary hypertension of the newborn. The pooled analysis showed…
A new analysis shows bosentan therapy reduces treatment failure for newborns with persistent pulmonary hypertension compared to control trea…
Hypertension care cascade under dual guideline criteria was analyzed in 238,738 adults from Peru
Primary Care & Family Medicine Guideline
Hypertension care cascade under dual guideline criteria was analyzed in 238,738 adults from Peru Peru adults with high blood pressure face gaps in standard care guidelines
This repeated cross-sectional analysis examined the hypertension care cascade under dual guideline criteria (2023 ESH and 2025 ACC/AHA) in 2…
A look at 238,738 adults in Peru shows how often high blood pressure care falls short of current expert recommendations.
Renal denervation combined with pulmonary vein isolation increases freedom from atrial fibrillation risk in resistant hypertension patients
Cardiology Meta-analysis
Renal denervation combined with pulmonary vein isolation increases freedom from atrial fibrillation risk in resistant hypertension patients Renal denervation may help resistant hypertension patients with heart issues
This systematic review and meta-analysis evaluated renal denervation in patients with resistant hypertension. The pooled analysis included 8…
A meta-analysis suggests renal denervation improves heart and sleep markers in patients with resistant hypertension, though larger trials ar…

Questions about Pulmonary Arterial Hypertension

Does the new drug Winrevair improve exercise capacity for people with Pulmonary Arterial Hypertension?

Yes, the drug Winrevair (sotatercept) improves exercise capacity in adults with pulmonary arterial hypertension by increasing distance walked and oxygen use.

Full answer →
Can parenteral treprostinil help children with pediatric Pulmonary Arterial Hypertension based on recent studies?

Yes, recent studies show parenteral treprostinil can improve outcomes in children with PAH, though evidence is from observational studies, not large trials.

Full answer →